| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7a727fc8ed43cc6e479daaf2f04853df |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-61
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-28122
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-707
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5767
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-576
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-10 |
| filingDate |
1995-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2001-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f34e09f017ced8a35966155606cdd956
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_323e08b6c376d62b8e518fed12be01aa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_640fcbfdbdc020dda9f15c3d0b483451
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a6ef2435d34eacd8f9d40985e55ba78c |
| publicationDate |
2001-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-6291641-B1 |
| titleOfInvention |
Hepatitis E virus antigens and uses therefor |
| abstract |
Antigens are provided which are derived from the enterically transmitted non-A/non-B viral hepatitis agent, known as hepatitis E virus (HEV). The HEV antigens and in particular, a soluble 62 kDa species of the capsid protein encoded by ORF2, are immunoreactive with sera from individuals infected with HEV. The 62K antigen may be produced by a baculovirus expression vector and forms virus-like particles (VLPs). The antigens are useful as diagnostic reagents in diagnostic methods and kits for determining infection of an individual with HEV. The antigens are also useful in vaccine compositions effective in methods for preventing HEV infection. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010003281-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2322625-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7786264-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006233822-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2501809-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2493249-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1452541-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1452541-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9428554-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2501568-C1 |
| priorityDate |
1988-06-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |